Navigation Links
AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting
Date:10/1/2013

13, AbbVie's investigational DAA regimen with and without ribavirin for HCV genotype 1 was designated as a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA). This designation is intended to help expedite the development of drugs for serious or life-threatening conditions and is based in part on preliminary clinical evidence demonstrating a drug or regimen may have substantial improvement on at least one clinically significant endpoint compared to available therapy.

AbbVie Hepatitis C Data at AASLD 2013

  • Trends in Liver-Related Healthcare Resource Utilization for HCV-Infected Individuals in the US: 2002-2010
    Poster #367
    November 2nd, 2:00PM ET; Poster Hall
    This study analyzed years 2002-2010 of the National Inpatient Sample (NIS) data set of hospital admissions from the Healthcare Cost and Utilization Project (HCUP) to determine the number of adult (age 20+ years) liver-related hospital admissions occurring in HCV-infected patients (identified by ICD-9 codes).
  • Interferon- and Ribavirin-free Regimen of ABT-450/r + ABT-267 in HCV Genotype 1b-infected Treatment-Naïve Patients and Prior Null Responders
    Oral Presentation: Parallel Session 75
    November 3rd, 5:15PM ET; Hall E
    This oral presentation includes data from the phase IIb PEARL-I study, which examines an interferon-free, ribavirin-free investigational regimen of ABT-450/r plus ABT-267 in 82 patients with HCV genotype 1b.
  • Low Relapse Rate Leads to High Concordance of SVR4 and SVR12 with SVR24 After Treatment with ABT-450/r, ABT-267, ABT-333 + Ribavirin in Patients with Chronic HCV Genotype 1 Infection in the AVIATOR Study
    Poster #1089
    November 3rd, 8:00AM ET; Poster Hall
    This study evaluated the concordance of SVR24 with rapid virologic response (RVR), SVR4 and SVR12 in treatment groups from the phase IIb AVIATOR study in 247 patients.
  • High Medication Adherence in HCV-Infected Patients Ta
    '/>"/>

  • SOURCE AbbVie Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
    2. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
    3. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
    4. AbbVie Declares Quarterly Dividend
    5. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
    6. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
    7. AbbVie to Participate in 2013 Jeffries Global Healthcare Conference
    8. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
    9. AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohns Disease
    10. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
    11. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/25/2014)... 25, 2014 Research and Markets ... Diagnostic Devices Market 2014-2018" report to their offering. ... About Ophthalmic Diagnostic Device An ophthalmic ... a defect or deficiency in the human visual pathway. ... such as presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, and ...
    (Date:7/25/2014)... Ore. , July 25, 2014  Semler ... an emerging medical risk assessment company that develops ... patients and evaluating chronic diseases, today reported financial ... ended June 30, 2014. "The ... for Semler," said Doug Murphy-Chutorian , M.D., ...
    (Date:7/25/2014)... , July 25, 2014  Arena Pharmaceuticals, Inc. ... provide a corporate update and report second quarter 2014 ... on Friday, August 1, 2014. That same day, Arena ... a.m. Eastern Time (5:30 a.m. Pacific Time). ... 877.643.7155 for domestic callers and 914.495.8552 for international callers. ...
    Breaking Medicine Technology:Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3
    ... 10, 2011 Sildenafil, a drug used to ... possible use -- helping children and young adults ... Sildenafil significantly improved measures of exercise performance during ... according to researchers from The Children,s Hospital of ...
    ... seek ways to reduce Medicaid spending, they should start by ... model to the more efficient model used in some parts ... finds that the program could save $473 million over ... more like those in Medicare and commercial plans. Governors Chris ...
    Cached Medicine Technology:Exercise Performance in Children and Young Adults with Single Ventricle Heart Disease Improves with Use of Drug for Erectile Dysfunction 2Exercise Performance in Children and Young Adults with Single Ventricle Heart Disease Improves with Use of Drug for Erectile Dysfunction 3Budget Solution? Modernizing Medicaid Pharmacy Could Save Florida $473 Million 2
    (Date:7/26/2014)... July 26, 2014 As the ... the true vision of Xoçai is ... its exclusive and healthy chocolate products. One such ... of cacao, açaí berries and blueberries, an ingredient ... high-antioxidant blend is utilized in all of Xoçai ...
    (Date:7/25/2014)... Dental Perfection, a Derby cosmetic dentist ... general dentistry, clear braces and much more, has just ... in Derby. The new practice, which is scheduled to ... in Littleover, Derby. Patients may already pre-register for the ... dental practice, which is headed by Invisalign specialist and ...
    (Date:7/25/2014)... Dallas, Texas (PRWEB) July 26, 2014 ... Global and China Gel Permeation Chromatography Industryā€¯ ... on the Global and China Gel Permeation ... Permeation Chromatography information, including Gel Permeation Chromatography ... as well as industry overview. This research ...
    (Date:7/25/2014)... July 25, 2014 In recent years, men ... eager to reverse the symptoms associated with age-related testosterone decline. ... at large, a new case study from Renew ... of testosterone therapy using bioidentical hormones. , The case ... from Seattle who found himself beginning to feel the effects ...
    (Date:7/25/2014)... American motor vehicle owners who are at higher ... premiums for vehicle insurance on average. The Quotes Pros ... SR22 insurance for high risk motorists this year at ... of local agencies providing direct price quotations for risk ... available for any car owner to access. One advantage ...
    Breaking Medicine News(10 mins):Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 2Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 3Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 4Health News:Derby Cosmetic Dentist Dental Perfection to Open New Practice in Littleover, Derby this September 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:SR22 Insurance for High Risk Motorists Added to Local Quotes System at Insurer Website Online 2
    ... , , , ... Costs Will Increase , , ... Director Douglass Elmendorf about current legislative drafts proposed by the Senate and ... care costs in the U.S. -- chronic disease. , ...
    ... the treatment of disease ,The team, led ... Research at the University of Copenhagen and the Max Planck ... in 1,750 different proteins. "This is more than ... of known acetylation switches by a factor of six, and ...
    ... prevention, treatment and care throughout Europe by improving communications within ... the launch of a new website: www.eurocancercoms.eu . The ... from researchers and doctors to patients. The ... Oncology and is led by ECCO the European CanCer ...
    ... only four sites across the country to participate in a ... investigate the effectiveness of a chemotherapeutic agent, ThermoDox, used in ... treating recurrent chest wall breast cancer. Recurrent chest ... on the chest wall, most commonly presenting in the skin ...
    ... are diagnosed with pancreatic cancer. Few live very long, ... after diagnosis. There,s new hope, though, from the ... University,s Faculty of Life Sciences. His drug compound Salirasib ... passed Phase I/II clinical trials. The drug, given in ...
    ... at Ben-Gurion University of the Negev (BGU) have conducted a ... adolescents, demonstrating that strong social support from friends is a ... to be the first of its type, was published in ... The American Academy of Pediatrics. ...
    Cached Medicine News:Health News:PFCD Urges Congress to Address Real Cost-Driver in Health Reform in Light of New CBO Statement 2Health News:New Web site launches $1.7 million project to improve European cancer communications 2Health News:New Web site launches $1.7 million project to improve European cancer communications 3Health News:RI Hospital first in country to enroll patient in new study for recurrent chest wall breast cancer 2Health News:New drug candidate prolongs the lives of pancreatic cancer patients 2Health News:Social support buffers adolescent depression after terrorist attacks: Ben-Gurion University 2
    PDA format of the well-known standard antimicrobial reference....
    PDA application providing a complete guide for the diagnosis and management of electrolyte disorders....
    Contains the most common procedures from all orthopedic sub-specialties organized by body area....
    Consists of the print and PDA versions of Harrison's Manual of Medicine 15th Edition. Provides high-end medical content via PDA....
    Medicine Products: